The First Hospital of Jilin University, Jilin University, Changchun, People's Republic of China.
Department of Cancer Center, the First Hospital of Jilin University, Changchun, People's Republic of China.
Drug Des Devel Ther. 2022 Aug 3;16:2497-2507. doi: 10.2147/DDDT.S373726. eCollection 2022.
Venous thromboembolism (VTE) is associated with increased morbidity and mortality, decreased quality of life, and higher economic burden in patients with cancer. Currently, the treatment of VTE in patients with cancer is particularly challenging. For many years, low molecular weight heparin (LMWHs) has been the standard for the treatment of cancer-associated VTE. Recently, the introduction of new oral anticoagulants (NOACs) may offer an oral anticoagulant option for some patients with cancer-associated thrombosis (CAT) as a growing body of literature supports the use of NOACs in the setting of CAT. With the use of NOAC as a new option in the management of CAT, clinicians now face several choices for the individual cancer patient with VTE. We need a more in-depth understanding of the drug properties, efficacy and safety, economic analysis that allows us to choose the most appropriate treatment for each patient. In the review, we will present an overview of CAT management, discuss the available evidence, economic costs for NOACs in the treatment of CAT, and seek to provide the best range of treatments for cancer patients.
静脉血栓栓塞症（VTE）与癌症患者的发病率和死亡率增加、生活质量下降以及经济负担加重有关。目前，癌症患者 VTE 的治疗极具挑战性。多年来，低分子肝素（LMWHs）一直是癌症相关 VTE 治疗的标准。最近，新型口服抗凝剂（NOACs）的引入可能为一些癌症相关血栓形成（CAT）患者提供口服抗凝剂选择，因为越来越多的文献支持在 CAT 中使用 NOACs。随着 NOAC 作为 CAT 管理的新选择，临床医生现在需要为每个 VTE 癌症患者做出多种选择。我们需要更深入地了解药物特性、疗效和安全性、经济分析，以便为每位患者选择最合适的治疗方法。在综述中，我们将介绍 CAT 管理的概述，讨论现有证据，以及 NOAC 治疗 CAT 的经济成本，并寻求为癌症患者提供最佳治疗范围。
